Medicare is again proposing cuts to payments for drugs purchased through the 340B program, reigniting a heated debate over the discount system. The latest proposal reduces reimbursement for 340B drugs, targeting a program that provides discounted medications to hospitals serving low-income patients.
The 340B program has long faced controversy, with hospitals arguing it is essential for their financial viability. Critics contend that some hospitals profit unduly from the discounts without passing savings to patients. The new proposal follows previous attempts to rein in program costs.
Lawmakers have separately intervened in a dispute between Eli Lilly and hospitals over 340B discounts. They urged the Department of Health and Human Services to force Eli Lilly to provide the discounts, which the company has reportedly restricted. The dual actions reflect growing scrutiny of the program from multiple angles.
If enacted, the payment cuts could reduce revenue for safety-net hospitals that rely on 340B savings to fund uncompensated care. These facilities may face tighter budgets, potentially affecting services for vulnerable populations. Meanwhile, drugmakers like Eli Lilly stand to benefit from reduced discounts.
The outcome remains uncertain, as past Medicare cuts to the program faced legal challenges and congressional pushback. Analysts expect continued lobbying from both hospital groups and pharmaceutical firms.